Norethindrone Acetate/Ethinyl Estradiol
Brand Names: Larin 1.5/30, Microgestin 1.5/30, Femlyv, Microgestin 1/20, Larin 1/20, Loestrin Fe
Methodology & AI Transparency ⓘ
Norethindrone Acetate/Ethinyl Estradiol Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Indications and usage larin:™ 1.5/30 is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.
- 2 Real-world patient consensus: Tracked across 8 patient dosage logs with a 84% satisfaction benchmark (RxCUI 1359022).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $7.17 wholesale mail-order against $34.50 retail pharmacy pricing.
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Norethindrone Acetate/Ethinyl Estradiol: nausea (9.4%), headache (7.5%), dizziness (5.3%).
Ask our AI Specialists anything about Norethindrone Acetate/Ethinyl Estradiol
Norethindrone Acetate/Ethinyl Estradiol Mechanism, CYP450 Pathways & DailyMed Monograph
Indications and usage larin:™ 1.5/30 is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Oral contraceptives are highly effective. Table I lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates. table1
CLINICAL PHARMACOLOGY Combination oral contraceptives act by suppression of gonadotropins. Although the primary mechanism of this action is inhibition of ovulation, other alterations include changes in the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the endometrium (which reduce the likelihood of implantation). Pharmacokinetics The pharmacokinetics of LARIN™ 1.5/30 has not been characterized; however, the following pharmacokinetic information regarding norethindrone acetate and ethinyl estradiol is taken from the literature.
Systemic exposure to Norethindrone Acetate/Ethinyl Estradiol reflects F ≈ 62%–74% systemic availability after standard oral Norethindrone Acetate/Ethinyl Estradiol administration absorption kinetics and mixed metabolic conjugation and unchanged urinary excretion across norethindrone acetate/ethinyl estradiol regimens, sustaining receptor engagement across a Terminal t½ estimated at 4–15 hrs depending on renal/hepatic reserve (Norethindrone Acetate/Ethinyl Estradiol) half-life window (time to peak concentration spans 1 to 3 hrs under norethindrone acetate/ethinyl estradiol maintenance response profile).
Dosing protocols (Kit or 1mg-20mcg Blister Pack of 28 Tablets or 1.5mg-30mcg Blister Pack of 28 Tablets or 0.5mg-2.5mcg Pack of Tablets or 1mg-5mcg Pack of Tablets) balance efficacy (84.00% patient satisfaction across 8 logs) against nausea (9.4% of reports), headache (7.5% of reports), fatigue (5.5% of reports), with strict avoidance in documented intolerance or hypersensitivity reaction involving norethindrone acetate/ethinyl estradiol (birth control agent); concurrent restricted medications flagged in section 4/7 of the norethindrone acetate/ethinyl estradiol dailymed monograph (1359022).
Assess baseline hepatic panels and interacting prescriptions when starting Norethindrone Acetate/Ethinyl Estradiol (birth control agent).
Unstandardized herbal extracts may interact pharmacodynamically with Norethindrone Acetate/Ethinyl Estradiol maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Documented intolerance or hypersensitivity reaction involving Norethindrone Acetate/Ethinyl Estradiol (birth control agent)
- Concurrent restricted medications flagged in Section 4/7 of the Norethindrone Acetate/Ethinyl Estradiol DailyMed monograph (1359022)
Logged Side-Effect Incidence (8 Reports)
Norethindrone Acetate/Ethinyl Estradiol Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Norethindrone Acetate/Ethinyl Estradiol)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Evidence for tissue selectivity of the synthetic androgen 7 These results demonstrate for the first time in humans the selectivity of MENT in tissues dependent on 5 alpha-reductase. The Journal of clinical endocrinology and metabolism • 2003-06-15 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 12788888 ↗ |
Norethindrone Acetate/Ethinyl Estradiol Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.3169/unit (~$9.51/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $7.17 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $34.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 8 Anonymous DotMD Community Micro-Logs | $8.25 / mo | View logs ↓ |
Norethindrone Acetate/Ethinyl Estradiol Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Norethindrone Acetate/Ethinyl Estradiol RxNorm Concept ID | 1359022 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.3169 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $7.17 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 84.00% Worth It (8 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Norethindrone Acetate/Ethinyl Estradiol Patient Community, Cohort Filters & Dosage Logs
Cross-verified Norethindrone Acetate/Ethinyl Estradiol (birth control agent) monograph synthesizing RxNorm 1359022, openFDA FAERS signals, and $7.17–$34.50 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Norethindrone Acetate/Ethinyl Estradiol community threads and patient logs by age, biological sex, dosage, and treatment duration.